• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Retina >INTRAVITREAL PEGAPTANIB SODIUM (MACUGEN) FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION A Morphologic and Functional Study
【24h】

INTRAVITREAL PEGAPTANIB SODIUM (MACUGEN) FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION A Morphologic and Functional Study

机译：腹腔内PEGAPTANIB钠（致癌物）治疗肌膜脉络膜神经硬化的形态学和功能研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: To report the morphologic and functional outcomes resulting from the use of intravitreal pegaptanib (IVP) sodium (Macugen) in patients with myopic choroidal neovascu larization. Methods: An open-label, nonrandomized, prospective clinical trial was performed. Morphologic outcome, such as foveal thickness, was assessed by optical coherence tomography, whereas functional outcomes were assessed by best-corrected visual acuity and microperimetry. Treatment protocol consisted of 3 consecutive IVP (0.3 mg/0.05 mL; baseline, 6th week, and 12th week). Follow-up checks were scheduled at the following intervals: baseline, 18, 24, 36, and 48 weeks. Results: Twenty eyes from 20 patients were studied. All patients completed follow-up at 48 weeks. After IVP, a significant decrease in foveal thickness occurred (-20%), and at the end of follow-up, choroidal neovascularization closure was obtained in all eyes. An improvement of functional parameters was recorded in all patients (best-corrected visual acuity from 25.5 +- 8.09 letters to 45.5 +- 8.16 letters, P < 0.0001; microperimetry from 8.40 +- 2.14 dB to 10.8 +- 2.05 dB, P < 0.01). The mean number of IVP was 3, and none of patients met the re-treatment criterion during the entire follow-up period. Neither ocular nor systemic side effects were observed. Conclusion: The findings demonstrate that the selective inhibition of VEGF-165 isoform by IVP is an effective treatment for myopic choroidal neovascularization.
机译：背景：报道近视脉络膜新生血管患者使用玻璃体内培加他尼（IVP）钠（Macugen）所产生的形态和功能结果。方法：进行了一项开放标签，非随机，前瞻性临床试验。形态学结果，如中央凹厚度，是通过光学相干断层扫描技术评估的，而功能结果是通过最佳矫正的视敏度和显微视野测定的。治疗方案包括3个连续的IVP（0.3 mg / 0.05 mL;基线，第6周和第12周）。定期检查的间隔时间为：基线，18、24、36和48周。结果：研究了来自20例患者的20眼。所有患者在48周时均完成了随访。 IVP后，中央凹厚度明显减少（-20％），在随访结束时，所有眼睛均获得脉络膜新生血管闭合。记录了所有患者的功能参数改善情况（最佳矫正视力从25.5±8.09​​字母增至45.5±8.16字母，P <0.0001;显微视野法从8.40 + 2.14 dB增至10.8 +-2.05 dB，P <0.01 ）。 IVP的平均数为3，并且在整个随访期间均无患者符合再治疗标准。既没有观察到眼或全身的副作用。结论：研究结果表明，IVP对VEGF-165亚型的选择性抑制是治疗近视脉络膜新生血管的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号